Gonasi Set (Human Chorionic Gonadotropin)

Gonasi Set is indicated for several fertility‑related purposes in assisted reproductive technology.

• Induction of ovulation in women with anovulatory or oligo‑ovulatory disorders.
• Luteal phase support following ovulation induction or assisted conception cycles.
• Treatment of infertility associated with inadequate endogenous hCG production.
• Use in combination with gonadotropin‑releasing hormone (GnRH) protocols to trigger final oocyte maturation.
• Support of spermatogenesis in selected male infertility cases (off‑label in some regions).

Side effects reported with Gonasi Set vary in frequency and severity; they are generally related to the injection site or hormonal activity.

Common

• Injection‑site pain, redness, or swelling.
• Mild headache or fatigue.
• Nausea or mild abdominal discomfort.
• Temporary ovarian enlargement or cyst formation.
• Breast tenderness or mild edema.

Serious

• Ovarian hyperstimulation syndrome (OHSS) with rapid weight gain, ascites, or respiratory distress.
• Allergic reactions such as rash, itching, or anaphylaxis.
• Thromboembolic events including deep‑vein thrombosis.
• Ectopic pregnancy in the setting of assisted conception.

Before prescribing Gonasi Set, clinicians should evaluate patient history and monitor for conditions that could be worsened by hCG therapy.

• Confirm absence of active ovarian cysts or severe endometriosis.
• Assess risk factors for ovarian hyperstimulation syndrome, especially in polycystic ovary syndrome.
• Review personal or family history of thromboembolic disease.
• Ensure appropriate timing within the menstrual cycle to avoid premature luteinization.
• Monitor serum estradiol and hCG levels during treatment.
• Use caution in patients with uncontrolled thyroid disease due to hCG’s thyrotropic effect.

Gonasi Set may interact with other medications or hormonal agents, influencing efficacy or safety.

Avoid

• Concurrent use of other gonadotropins or hCG products, which can cause excessive hormonal stimulation.
• High‑dose estrogen therapy that may mask ovarian response.

Use with caution

• Anticoagulant or antiplatelet drugs, due to increased risk of thrombosis in OHSS.
• Thyroid hormone replacement, as hCG can affect thyroid function tests.
• Assisted reproductive protocols involving GnRH agonists or antagonists, requiring dose adjustments.